{
    "clinical_study": {
        "@rank": "50183", 
        "arm_group": [
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) - Dose A", 
                "arm_group_type": "Experimental", 
                "description": "alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.\nalirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
            }, 
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) - Dose B", 
                "arm_group_type": "Experimental", 
                "description": "alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm."
            }, 
            {
                "arm_group_label": "alirocumab SAR236553 (REGN727) - Dose C", 
                "arm_group_type": "Experimental", 
                "description": "alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553\n      (REGN727) administered at 3 different injection sites in healthy subjects.\n\n      Secondary Objectives:\n\n        -  To assess the pharmacodynamic effect of a single subcutaneous dose of alirocumab\n           SAR236553 (REGN727) on serum low-density lipoprotein cholesterol and other lipids and\n           apolipoproteins.\n\n        -  To assess the safety of a single subcutaneous dose of alirocumab SAR236553 (REGN727).\n\n        -  To assess the immunogenicity of a single subcutaneous dose of alirocumab SAR236553\n           (REGN727)."
        }, 
        "brief_title": "Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "detailed_description": {
            "textblock": "Total duration of the study per subject is about 15 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Healthy subjects.\n\n        Exclusion criteria:\n\n        Healthy subjects with history or presence of clinically relevant illness.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785329", 
            "org_study_id": "BDR13362", 
            "secondary_id": [
                "2012-005005-40", 
                "U1111-1134-2618"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "alirocumab SAR236553 (REGN727) - Dose A", 
                "alirocumab SAR236553 (REGN727) - Dose B", 
                "alirocumab SAR236553 (REGN727) - Dose C"
            ], 
            "description": "Pharmaceutical form:Solution for injection Route of administration: Subcutaneous", 
            "intervention_name": "alirocumab SAR236553 (REGN727)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }, 
                "name": "Investigational Site Number 826001"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assessment of the serum concentrations of alirocumab SAR236553 (REGN727) after a single subcutaneous administration at 3 different injection sites in healthy subjects as a measure of the pharmacokinetics of this investigational medicinal product.", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of the serum concentrations of low-density lipoprotein cholesterol after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the pharmacodynamic effect of this investigational medicinal product.", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Assessment of the number of subjects with adverse events after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the safety/tolerability of this investigational medicinal product.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Assessment of the serum concentration of anti-drug antibodies after a single subcutaneous dose of alirocumab SAR236553 (REGN727) as a measure of the immunogenicity of this investigational medicinal product.", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}